PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
er the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/771,418-Conf. #4060 Application Number **FEE TRANSMITTAL** February 5, 2004 Filing Date First Named Inventor Henrik S. Olsen

F01112003				Examiner Name		M. A. Belyavskyi				
Applicant claims small entity status. See 37 CFR 1.27				Art Unit		1644				
TOTAL AMOUNT OF PAYMENT (\$) 0.00			/	Attorney Docket No.		PF363C2				
METHOD OF PAYMENT (check all that apply)										
Check Credit Card Money Order None Other (please identify):										
x Deposit Account Deposit Account Number: 08-3425 Deposit Account Name: Human Genome Sciences, Inc.										
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)										
x Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee										
Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17										
FEE CALCULATION										
1. BASIC FILING, SEARCH	I, AND EXA	MINATION FE	ES							
	FILIN	IG FEES	SEAF	RCH FEES	EXAMIN	IATION FEES				
Application Type	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees	Paid (\$)		
Utility	300	150	500	250	200	100				
Design	200	100	100	50	130	65				
Plant	200	100	300	150	160	80				
Reissuc	300	150	500	250	600	300				
Provisional	200	100	0	0	0	0				
2. EXCESS CLAIM FEES								Small Entity		
Fee Description							Fee (\$)	<u>Fee (\$)</u>		
Each claim over 20 (including Reissues)							50	25		
Each independent claim over 3 (including Reissues)							200 360	100		
Multiple dependent claims	01-1	F (A)	Fac Dai	(d)		ultiala Dananda		180		
<u>Total Claims</u> <u>Extra Claims</u> <u>Fee (\$)</u> <u>Fee F</u>			Fee Pai	u (a)	-	ultiple Depende	ee Paid (-		
0063 =	× _	= _			re	<u>e (\$) </u>	ee Falu (<u>#1</u>		
Indep. Claims Extra	Claims	Fee (\$)	Fee Pai	d (\$)						
4 -6=		= =								
3. APPLICATION SIZE FEE										
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50										
					or small er	itity) for each ac	dditional 5	0		
sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)										
100 =							=			
4. OTHER FEE(S) Fees Paid (\$)										
Non-English Specification, \$130 fee (no small entity discount)										
Other (e.g., late filing surcharge):										
						·				

SUBMITTED BY		7 1	/		. ,		.
Signature	Kul	-11/14	2	Registration No. (Attorney/Agent)	40,302	Telephone	(301) 610-5771
Name (Print/Type)	Kenley K.	Hoover				Date Feb	nay 15, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Olsen et al.

Application No.: 10/771,418

Filed: February 5, 2004

For: Antibodies to Fc Receptor-like V Polypeptides

(as amended herein)

Docket No.: PF363C2

Confirmation No.: 4060

Art Unit: 1644

Examiner: M. A. Belyavskyi

REPLY AND AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed October 15, 2004 (Paper No. 92004), please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith: (a) Fee Transmittal Sheet in duplicate, with appropriate fee; (b) a Petition for an Extension of Time (1 month, to and including February 15, 2005); (c) Resubmission of copy of Form PTO/SB/08 (originally submitted on August 16, 2004); (d) Resubmission of copies of references AE-BJ; and (e) Exhibit A.

Amendments to the Title begin on page 2.

Amendments to the claims begin on page 3.

Remarks begin on page 11.